Low-Dose of Bergamot-Derived Polyphenolic Fraction (BPF) Did Not Improve Metabolic Parameters in Second Generation Antipsychotics-Treated Patients: Results from a 60-days Open-Label Study

Metabolic outcomes of bergamot polyphenolic fraction administration in patients treated with second-generation antipsychotics: a pilot study

(2017) Antonio Bruno et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study

(2016) Peter P. Toth et al.   Frontiers in Pharmacology

Narrative Review: Statin-Related Myopathy

(2013) Tisha R. Joy   ANNALS OF INTERNAL MEDICINE

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

(2012) et al.   EUROPEAN HEART JOURNAL

Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study

(2011) Fuminari Misawa et al.   BMC Psychiatry

Nutraceuticals in Diabetes and Metabolic Syndrome

(2010) Giovanni Davì et al.   Cardiovascular Therapeutics

Hypolipemic and hypoglycaemic activity of bergamot polyphenols: From animal models to human studies

(2010) Vincenzo Mollace et al.   FITOTERAPIA

Basic biochemical mechanisms behind the health benefits of polyphenols

(2010) Cesar G. Fraga et al.   MOLECULAR ASPECTS OF MEDICINE

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design

(2010) Roberto Coccurello et al.   PHARMACOLOGY & THERAPEUTICS

The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials

(2009) Alawi A. Alsheikh-Ali et al.   Current Atherosclerosis Reports

30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice

(2009) Roberto Coccurello et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms

(2009) Gavin P Reynolds et al.   PHARMACOLOGY & THERAPEUTICS